Page last updated: 2024-12-06

oxazepam hemisuccinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxazepam hemisuccinate is a water-soluble prodrug of oxazepam, a benzodiazepine used to treat anxiety disorders. It is synthesized by reacting oxazepam with succinic anhydride. Due to its increased water solubility compared to oxazepam, oxazepam hemisuccinate offers advantages in terms of bioavailability and ease of administration, particularly for intravenous injection. It exerts its therapeutic effects by binding to benzodiazepine receptors in the central nervous system, leading to anxiolytic, sedative, and muscle relaxant effects. Oxazepam hemisuccinate is studied extensively to investigate its efficacy and safety in treating various anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. The compound's rapid onset of action and relatively short half-life make it a valuable tool for managing acute anxiety episodes. Research also focuses on its potential applications in managing withdrawal symptoms associated with alcohol and benzodiazepine dependence.'

oxazepam hemisuccinate: RN given refers to cpd without isomeric designation; structure in Negwer, 5th ed, #3843 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36754
CHEMBL ID60886
MeSH IDM0081558

Synonyms (34)

Synonym
oxazepam hemisuccinate
sas 538
empracil
oxazepam succinate
7-chloro-1,3-dihydro-3-hemisuccinyloxy-2h-1,4-benzodiazepin-2-one
(rs)-oxazepam h
(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-benzo-1,4-diazepin-3-yl) hydrogen succinate
brn 0769233
einecs 225-175-2
succinic acid, monoester with 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepin-2-one
butanedioic acid, mono(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl) ester
nulans
CHEMBL60886
4-[(7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)oxy]-4-oxobutanoic acid
4700-56-5
dce8700inn ,
(+-)-oxazepam hemisuccinate
(+-)-oxazepam succinate
unii-dce8700inn
(+/-)-oxazepam hemisuccinate
butanedioic acid, 1-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl) ester
sas-538
(+/-)-oxazepam succinate
oxazepam succinate [who-dd]
(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-benzo-1,4-diazepin-3-yl)hydrogen succinate
4-[(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepin-3-yl)oxy]-4-oxobutanoic acid
AKOS030227984
123632-29-1
DTXSID70924562
4-[(7-chloro-2-hydroxy-5-phenyl-3h-1,4-benzodiazepin-3-yl)oxy]-4-oxobutanoic acid
AS-44342
mfcd01683260
4-((7-chloro-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)oxy)-4-oxobutanoic acid
Q27276327

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID23479Partition coefficient (logP)1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID194133ED50 value was reported as log1/C, which is the concentration that caused fourfold increase of lever pressing in 50% of rats for the punished schedule; ND means no data1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID194131ED50 value was reported as log1/C, which is the concentration required to reduce locomotor activity by 50% in rats1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID194135ED50 value was reported as log1/C, which is the concentration that would decrease to a half the lever pressing in 50% of rats for the non punished schedule; ND means no data1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.44 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]